STRUCTURE OF THE ALKALI‐LABILE PRODUCT FORMED DURING IRON(II)‐BLEOMYCIN‐MEDIATED DNA STRAND SCISSION

STRUCTURE OF THE ALKALI‐LABILE PRODUCT FORMED DURING IRON(II)‐BLEOMYCIN‐MEDIATED DNA STRAND SCISSION
复制标题

铁 (II)-博莱霉素介导的 DNA 链断裂过程中形成的碱不稳定产物的结构

DOI:
10.1002/chin.198543352
复制
发表时间:
1985
期刊:
ChemInform
影响因子:
--
通讯作者:
S. Hecht
S. Hecht
中科院分区:
--
文献类型:
--
作者:
H. Sugiyama;Cheng Xu;N. Murugesan;S. Hecht

文献摘要

被引文献

相似文献

博来霉素是一组糖肽衍生的抗生素,临床上用于治疗某些恶性肿瘤,包括鳞状细胞癌和霍奇金病。1博莱霉素似乎主要在DNA链断裂水平介导其治疗作用,2 3 a转化可由四种金属霉素中的任何一种影响。3 02-依赖的(1)(a)Hecht,S. M.在“博莱霉素:化学、生物化学和生物学方面”; Hecht,S. M.,编辑; Springer-Verlag:纽约,1979年; p 1 ff。(b)梅泽,H.在“Medicinal Chemistry Series:Anticancer Agents Based on Natural Product Models”; Cassady,J.M.,Douros,J.D.,编辑;学术出版社:纽约,1980年;第十六卷,第148页及其后。(c)波维克湖F.在“Molecular Aspects of Anti-cancer Drug Action”中; Neidle,S.,Waring,M. J.,编辑; Macmillan:伦敦,1983年;第157页及以后。(2)(a)Umezawa,H.在“博莱霉素:化学、生物化学和生物学方面”; Hecht,S. M.,编辑; Springer-Verlag:纽约,1979年;第24页及以后。(b)Suzuki,H.;永井; Yamaki,T.; Tanaka,N.;梅泽,H. J. Antibiot.(东京)1969年,22,446。(3)(a)Sausville,E.一、Peisach,J.; Horwitz,S. B。生物化学1978,17,2740。(b)埃克菲尔德湾M.;罗德里格斯湖,澳-地的O.;赫克特,S。M.; Chang,C.; Basus,V. J.; Oppenheimer,N. J. Biochemistry 1985,24,81. (c)埃克菲尔德湾M.; Murugesan,N.; Hecht,S. M. Inorg.Chem.1984,23,1496.(d)其他事项
The bleomycins are a group of glycopeptide-derived antibiotics employed clinically for the treatment of certain malignancies including squamous cell carcinomas and Hodgkin’s disease. 1 The bleomycins appear to mediate their therapeutic effects primarily at the level of DNA strand scission, 2 3a transformation that can be effected by any of four metallobleomycins. 3 The 02-dependent (1)(a) Hecht, S. M. In “Bleomycin: Chemical, Biochemical and Biological Aspects"; Hecht, S. M., Ed.; Springer-Verlag: New York, 1979; p 1 ff.(b) Umezawa, H. In “Medicinal Chemistry Series: Anticancer Agents Based on Natural Product Models”; Cassady, J. M., Douros, J. D., Eds.; Academic Press: New York, 1980; Vol. XVI, p 148 ff.(c) Povirk, L. F. In “Molecular Aspects of Anti-cancer Drug Action”; Neidle, S., Waring, M. J., Eds.; Macmillan: London, 1983; p 157 ff.(2)(a) Umezawa, H. In “Bleomycin: Chemical, Biochemical and Biological Aspects”; Hecht, S. M., Ed.; Springer-Verlag: New York, 1979; p 24 ff.(b) Suzuki, H.; Nagai, K.; Yamaki, T.; Tanaka, N.; Umezawa, H. J. Antibiot.(Tokyo) 1969, 22, 446.(3)(a) Sausville, E. A.; Peisach, J.; Horwitz, S. B. Biochemistry 1978, 17, 2740.(b) Ehrenfeld, G. M.; Rodriguez, L. O.; Hecht, S. M.; Chang, C.; Basus, V. J.; Oppenheimer, N. J. Biochemistry 1985, 24, 81.(c) Ehrenfeld, G. M.; Murugesan, N.; Hecht, S. M. Inorg. Chem. 1984, 23, 1496.(d)